Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors inside the central anxious program, conolidine modulates alternate molecular targets. A Science Advances review uncovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://michaelo257nib4.dreamyblogs.com/profile